The TH3RESA study, another phase III randomized trial, assessed PFS and OS with T-DM1 in comparison with treatment of physician’s choice in 602 advanced HER2-positive breast cancers previously treated with at least trastuzumab, lapatinib and a taxane. The gene discussed is ERBB2; the disease is breast cancer.